$Tonix Pharmaceuticals (TNXP.US)$ An interestingly bullish T...

$Tonix Pharmaceuticals (TNXP.US)$
An interestingly bullish TNXP take
NASDAQ proposed the above rule where companies do not get a 180-360 day compliance period to maintain >$1 share price if company preformed a reverse split within the prior year. If company preforms an RS and has already done an RS in the prior year, they will not get any grace period and immediately be delisted once price falls <$1 after RS. This rule is set to be approved on 11/21 (2 days from today).

As of now, TNXP has until February 2025 to get >$1 and until August 2025 to get >$1 with an extension, an extension being almost certain of approval due to their reason (drug almost approved).

If TNXP preforms another RS before June 2025, they will have no grace period (Feb/Aug ‘25) to be >$1 and be immediately delisted once share price falls <$1 after the RS (which I assure you will be well before Feb/Aug ‘25).

Why would TNXP RS again and lose their grace period? Feb/Aug ‘25 is plenty of time to be >$1 with 102 pending NDA. It makes absolutely no sense for TNXP to reverse split before June 2025.

If FDA accepts 102 NDA on 12/16, the PDUFA date will either be June ‘25 with priority, or October ‘25 without priority.

Possible scenarios in Dec ‘24:

FDA accepts NDA and TNXP share price is >$1 and retains $1+ and this whole problem goes away. Likely and bullish.

NDA is not accepted and TNXP crashes and burns. Falling <$.10 and is delisted. Likely and bearish.

TNXP is not >$1 after NDA acceptance, but gets priority review for June ‘25 PDUFA date and files Feb ‘25 delisting extension to Aug ‘25 in time for price to rise >$1 following 102 drug approval on PDUFA date (June). Likely and bullish.

TNXP is not >$1 after NDA acceptance and has PDUFA non priority review for Oct ‘25. TNXP files for Aug ‘25 extension and conducts another RS in June ‘25. Unlikely and bearish.

Thoughts?